Search for content, post, videos
Advertisement

Xbrane announce US FDA filing acceptance

Martin Åmark

The company has announced the acceptance of the supplemental Biologics License Application (sBLA) for a Lucentis (ranibizumab) biosimilar candidate by the US Food and Drug Administration.

The regulatory process can therefore be initiated with a Biosimilar User Fee Amendment (BsUFA) goal date of April 21st, 2024, states the company.

“Today’s sBLA acceptance marks an important step forward for increasing access to VEGF-a inhibitor therapy for all those who benefit from alternative treatment options,” says Martin Åmark, CEO, Xbrane. “Together with STADA and Bausch + Lomb, we will work closely with the FDA during the review process and, if approved, making this new biosimilar available to eye care professionals and their patients throughout the United States.”

Lucentis

The biosimilar candidate is a VEGF-a inhibitor, intended for the treatment of serious eye diseases such as wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion and myopic choroidal neovascularization. In 2018 Xbrane signed a co-development agreement with STADA and in May 2020, the companies signed an exclusive licensing agreement with Bausch + Lomb to commercialize the biosimilar candidate in the United States and Canada.

Supported by a Comparative Analytical Assessment

The FDA filing is supported by a comprehensive Comparative Analytical Assessment of the biosimilar candidate vs. Lucentis (ranibizumab) and positive data from a randomized, double-masked, multi-center study evaluating efficacy, safety, pharmacokinetics, and immunogenicity of the ranibizumab biosimilar in patients with wAMD. The biosimilar candidate met the primary endpoint in the study by demonstrating equivalent efficacy measured in improvement in best corrected visual acuity (BCVA) at week eight compared to Lucentis. Equivalence was determined because the two-sided 95% confidence interval around the difference in change in BCVA at week eight was within the pre-defined equivalence margin as agreed with the European Medicines Agency and FDA. Furthermore, no clinically meaningful differences on secondary endpoints regarding pharmacokinetic, safety and immunogenicity versus Lucentis were observed.

Photo of Martin Åmark: Xbrane

Advertisement